Isomorphic Labs is applying frontier AI to help unlock deeper scientific insights, faster breakthroughs, and life-changing medicines with an ambition to solve all disease.
The future is coming. A future enabled and enriched by the incredible power of machine learning. A future in which diseases are curtailed or cured starting with better and faster drug discovery.
Come and be part of an interdisciplinary team driving groundbreaking innovation and play a meaningful role in contributing towards us achieving our ambitious goals, while being a part of an inspiring and collaborative culture.
The world we want tomorrow is the one we’re building today. It starts with the culture at this company. It starts with you.
About Iso
Isomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.
Our name comes from the belief that there is an underlying symmetry between biology and information science. By harnessing AI’s powerful capabilities, we can use it to model complex biological phenomena to help design novel molecules, anticipate how drugs will perform and develop innovative medicines to treat and cure some of the world’s most devastating diseases.
We have built a world-leading drug design engine comprising AI models that are capable of working across multiple therapeutic areas and drug modalities. We are continually innovating on model architecture and developing cutting-edge capabilities to advance rational drug design.
Every day, and with each new breakthrough, we’re getting closer to the promise of digital biology, and achieving our ambitious mission to one day solve all disease with the help of AI.
Isomorphic Labs was launched in 2021 to advance human health by building on and beyond the Nobel prize-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.
Our name comes from the belief that there is an underlying symmetry between biology and information science. By harnessing AI’s powerful capabilities, we can use it to model complex biological phenomena to help design novel molecules, anticipate how drug candidates will perform in the clinic and develop medicines to treat and cure some of the world’s most devastating diseases.
At IsoLabs, we are committed to leveraging state-of-the-art AI to advance precision medicine paradigms and establish new benchmarks for both efficacy and safety by consistently delivering the optimal treatments to the appropriate patients at precisely the right time, which we expect to significantly enhance our overall probability of success.
Since our founding, we have grown a world-class interdisciplinary team led by founder and CEO Sir Demis Hassabis and President Max Jaderberg. We have built strategic drug discovery collaborations with partners including Eli Lilly, Novartis and Johnson & Johnson, with the Novartis collaboration expanding in February 2025 to double its original scope. Our internal drug candidate pipeline consists of multiple programs across oncology and immunology.
In March 2025, IsoLabs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet. In May 2026, IsoLabs raised $2.1 billion in a Series B financing round. This investment will power our world-leading AI drug design engine, scale our business globally and progress our drug candidate pipeline. The round was led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding our global capital base.Isomorphic Labs is scaling globally, with headquarters in London and offices in Lausanne, Switzerland and a US base in Cambridge, Massachusetts. We continue to progress our internal candidate programs towards the clinic while advancing across a broad range of modalities including small molecules, molecular glues, peptides, and antibodies.
Your impactWe are seeking a highly motivated and experienced Director of Nonclinical Safety to build our nonclinical safety function supporting programs in the Early Development phase.
Reporting directly to the Head of Early Development, you will serve as a key member of the Early Development team. In this critical role, you will be primarily responsible for defining and executing phase-appropriate nonclinical safety strategies as well as pioneering the integration of artificial intelligence in support of oncology and non-oncology programs.
Functional Leadership & Capability Building
- Lead, build, and scale the Nonclinical Safety function within an AI-first drug development environment.
- Serve as the primary internal expert for post-IND nonclinical safety ensuring quality, consistency, and scalability as compounds transition into clinical trials.
- Establish a critical data feedback loop: ensure high-quality data are fed back to computational teams to continuously train, validate, and refine our predictive nonclinical safety AI models.
Portfolio & Program Strategy
- Define and drive nonclinical safety and other translational strategies primarily for small molecule drug candidates in the Early Development phase across oncology and non-oncology indications.
- Execute seamlessly on post-IND (NDA/MAA-enabling) nonclinical toxicology work, including chronic, reproductive, and carcinogenicity studies as needed.
- Establish translational strategies by integrating exploratory nonclinical safety biomarkers and exposure-based modeling plans to predict and de-risk potential effects in humans.
- Integrate in silico safety predictions (e.g., off-target liabilities, digital pathology, predictive DILI models) with traditional data to help build robust, AI-augmented nonclinical safety profiles for compounds in development.
- Collaborate closely with colleagues in Preclinical Development, Clinical Pharmacology, Regulatory Affairs, Quality, and Pharmaceutical Sciences & Manufacturing to ensure the seamless development of drug candidates.
External Partnerships & Regulatory
- Leverage network of global CRO’s and consultants, ensuring data quality, timelines, and cost efficiency in a fast-paced environment.
- Lead nonclinical regulatory strategy and contribute to corresponding documentation, including INDs, IBs, DSURs, briefing books, and NDA/MAA modules (including USPI/labels).
- Represent Isomorphic Labs in regulatory interactions and global health authority meetings (FDA, EMA) as appropriate, leveraging cutting-edge AI and LLM tools to accelerate document drafting, data QC, and narrative generation.
- Participate in validating, presenting, and defending AI-derived safety data and predictive models in interactions with global health authorities (FDA, EMA) to advance the regulatory acceptance of computational toxicology.
- PhD, DVM, or equivalent in Cell & Molecular Biology, Toxicology, Pathology, Pharmacology, or a related field. Board certification in toxicology is desired.
- 12+ years of experience in nonclinical safety and toxicology in the biotech/pharma industry.
- Demonstrated success in small molecule drug development for oncology and non-oncology indications is required. Additional experience in biologics is a plus.
- A strong interest in, or hands-on experience with, computational toxicology, machine learning applications in safety assessment, or evaluating in silico predictive models.
- Experience in developing biologics and other novel platforms is highly desired.
- Proven track record advancing programs from discovery through post-IND clinical development and late-stage registration (NDA/BLA).
- Strong experience selecting, auditing, and managing external CRO vendors for GLP toxicology studies.
Attributes:
- Enterprise mindset; able to bridge the gap between computational AI teams and traditional drug development.
- A strong enthusiasm for operating in an AI-first environment and leveraging cutting-edge automation in daily workflows.
- Analytical and goal-oriented, with the ability to operate with urgency while maintaining the highest standards of scientific rigor and ethics.
- Strong communicator who can translate complex safety and biomarker and computational toxicology data into clear, audience-appropriate risk assessments, building trust across early development.
Culture and values
We are guided by our shared values. It's not about finding people who think and act in the same way. These values help to guide our work and will continue to strengthen it.
Thoughtful
Thoughtful at Iso is about curiosity, creativity and care. It is about good people doing good, rigorous and future-making science every single day.
Brave
Brave at Iso is about fearlessness, but it’s also about initiative and integrity. The scale of the challenge demands nothing less.
Determined
Determined at Iso is the way we pursue our goal. It’s a confidence in our hypothesis, as well as the urgency and agility needed to deliver on it. Because disease won’t wait, so neither should we.
Together
Together at Iso is about connection, collaboration across fields and catalytic relationships. It’s knowing that transformation is a group project, and remembering that what we’re doing will have a real impact on real people everywhere.
Creating an extraordinary company
We believe that to be successful we need a team with a range of skills and talents. We're building an environment where collaboration is fundamental, learning is shared and every employee feels supported and able to thrive. We value unique experiences, knowledge, backgrounds, and perspectives, and harness these qualities to create extraordinary impact.
We are committed to equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, disability, age, citizenship, marital, domestic or civil partnership status, sexual orientation, gender identity, pregnancy or related condition (including breastfeeding) or any other basis protected by applicable law. If you have a disability or additional need that requires accommodation, please do not hesitate to let us know.
Hybrid working
It’s hugely important for us to share knowledge and build strong relationships with each other, and we find it easier to do this if we spend time together in person. This is why we follow a hybrid model, and would require you to be able to come into the office 3 days a week (currently Tuesday, Wednesday, and one other day depending on which team you’re in). If you have additional needs that would prevent you from following this hybrid approach, we’d be happy to talk through these if you’re selected for an initial screening call.
Please note that when you submit an application, your data will be processed in line with our privacy policy.
>> Click to view other open roles at Isomorphic Labs
Skills Required
- PhD, DVM, or equivalent in Cell & Molecular Biology, Toxicology, Pathology, Pharmacology, or related field.
- Board certification in toxicology.
- 12+ years of experience in nonclinical safety and toxicology within biotech/pharma.
- Demonstrated success in small molecule drug development for oncology and non-oncology indications.
- Experience with biologics and other novel platforms.
- Hands-on experience or strong interest in computational toxicology, machine learning applications in safety assessment, or evaluating in silico predictive models.
- Proven track record advancing programs from discovery through post-IND clinical development and late-stage registration (NDA/BLA).
- Experience selecting, auditing, and managing external CRO vendors for GLP toxicology studies.
- Ability to work on-site in Cambridge three days per week (hybrid model).
What We Do
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.
